Concord Drugs Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Seelam Reddy

Chief Executive Officer (CEO)

₹6.0m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	2.8yrs
Participación del CEO	29.1%
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	4.2yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Seelam Reddy en comparación con los beneficios de Concord Drugs?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	₹10m
Sep 30 2023	n/a	n/a	₹17m
Jun 30 2023	n/a	n/a	₹13m
Mar 31 2023	₹6m	₹6m	₹10m
Dec 31 2022	n/a	n/a	₹9m
Sep 30 2022	n/a	n/a	₹8m
Jun 30 2022	n/a	n/a	₹11m
Mar 31 2022	₹4m	₹4m	₹16m
Dec 31 2021	n/a	n/a	₹19m
Sep 30 2021	n/a	n/a	₹42m
Jun 30 2021	n/a	n/a	₹38m
Mar 31 2021	₹2m	₹2m	₹33m
Dec 31 2020	n/a	n/a	₹30m
Sep 30 2020	n/a	n/a	₹4m
Jun 30 2020	n/a	n/a	₹4m
Mar 31 2020	₹1m	₹1m	₹3m
Dec 31 2019	n/a	n/a	₹4m
Sep 30 2019	n/a	n/a	₹4m
Jun 30 2019	n/a	n/a	₹4m
Mar 31 2019	₹2m	₹2m	₹4m

Compensación vs. Mercado: La compensación total de Seelam($USD71.96K) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD39.36K).

Compensación vs. Ingresos: La compensación de Seelam ha aumentado más de un 20% en el último año.

CEO

Seelam Reddy (54 yo)

2.8yrs

Permanencia

₹6,000,000

Compensación

Mr. Seelam Nagi Reddy served as Managing Director at Concord Drugs Limited until July 16, 2016 and served as its Compliance Officer. Mr. Reddy has been the Chairman and Whole-time Director of Concord Drugs...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Seelam Reddy	Chairman of the Board & MD	21.1yrs	₹6.00m	29.13% ₹ 114.6m
Seelam Reddy	CFO & Whole-Time Director	12.9yrs	₹2.40m	10% ₹ 39.4m
Seelam Manoj Reddy	Whole-Time Director	2.8yrs	₹2.40m	16.28% ₹ 64.1m
Kommula Reddy	Non-Executive Independent Director	5.2yrs	sin datos	0.50% ₹ 2.0m
Nagavenkata Hareesh Solleti	Non-Executive Independent Director	3.3yrs	sin datos	0.000010% ₹ 39.4
Sumeela Kasu	Independent Director	1.9yrs	sin datos	sin datos

4.2yrs

Permanencia media

34yo

Promedio de edad

Junta con experiencia: La junta directiva de 538965 se considera experimentada (4.1 años de antigüedad promedio).

Concord Drugs Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023

Less than half of directors are independent

Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer

Concord Drugs Limited Announces Director Changes

Recent updates

New minor risk - Revenue size

Third quarter 2024 earnings released: ₹0.24 loss per share (vs ₹0.52 profit in 3Q 2023)

Investor sentiment improves as stock rises 19%

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹0.60 (vs ₹0.21 in 2Q 2023)

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Concord Drugs Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 23%

Concord Drugs Limited to Report Q1, 2024 Results on Aug 14, 2023

Concord Drugs Limited to Report Q1, 2024 Results on Aug 14, 2023

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Full year 2023 earnings released: EPS: ₹1.06 (vs ₹1.82 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.52 (vs ₹0.48 in 3Q 2022)

Concord Drugs Limited Appoints Mr. Ankur Bisht as Company Secretary and Compliance Officer, Effective on February 16, 2023

Less than half of directors are independent

Concord Drugs Limited announced that it has received INR 10.364063 million in funding

Concord Drugs Limited Appoints RakshitSethiya as Company Secretary and Compliance Officer

Investor sentiment improved over the past week

Concord Drugs Limited to Report Q2, 2023 Results on Nov 14, 2022

Investor sentiment improved over the past week

Concord Drugs Limited to Report Q1, 2023 Results on Aug 06, 2022

Investor sentiment improved over the past week

Concord Drugs Limited Announces Director Changes

Concord Drugs Limited to Report Q4, 2022 Results on May 30, 2022

Concord Drugs Limited Announces Resignation of Jyoti Goyal as Company Secretary and Compliance Officer

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹0.52 (vs ₹0.092 in 2Q 2021)

Investor sentiment improved over the past week

Less than half of directors are independent

Less than half of directors are independent

First quarter 2022 earnings released: EPS ₹0.79 (vs ₹0.19 in 1Q 2021)

Non-Executive Independent Director Pathakota Reddy has left the company

Full year 2021 earnings released: EPS ₹3.75 (vs ₹0.38 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day high: ₹25.25

Third quarter 2021 earnings released: EPS ₹3.09 (vs ₹0.05 in 3Q 2020)

Concord Drugs Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day low: ₹21.75

Concord Drugs Limited, Annual General Meeting, Dec 29, 2020

Market pulls back on stock over the past week

New 90-day high: ₹19.35

First quarter earnings released

New 90-day high - ₹17.47

New 90-day low - ₹13.30

New 90-day low - ₹14.25

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Miembros de la Junta

Permanencia media

Promedio de edad